Encephalopathy after COVID-19 vaccination during treatment with nivolumab: A case report

3Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Your institution provides access to this article.

Abstract

Vaccination is useful for the prevention of COVID-19 and is recommended for everyone, especially people with a weakened immune system. However, various neurological complications have been reported following vaccination. Here, we report the case of a 25 years-old, Japanese man, who presented with acute encephalopathy two days after the second dose of the COVID-19 vaccine. He had been treated with nivolumab, a medication used to treat cancer. He had a high fever and was confused upon admission, and the antibody test was positive for anti-myelin oligodendrocyte glycoproteins. Abnormal signal intensity at the splenium corporis callosi was observed on diffusion-weighted imaging of the brain. We diagnosed him with autoimmune encephalitis and initiated intravenous methylprednisolone, after which, the patient's symptoms rapidly subsided.

Cite

CITATION STYLE

APA

Takenaka, M., Nakamori, M., Ishikawa, R., Aoki, S., & Maruyama, H. (2023). Encephalopathy after COVID-19 vaccination during treatment with nivolumab: A case report. Clinical Neurology and Neurosurgery, 226. https://doi.org/10.1016/j.clineuro.2023.107632

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free